Dec 13, 2018
GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion...
seen from Türkiye
seen from Japan
seen from United States
seen from Italy
seen from United States
seen from Canada
seen from Azerbaijan
seen from Germany
seen from Malaysia
seen from Australia
seen from United States
seen from China
seen from Norway
seen from Norway
seen from United Kingdom
seen from Italy
seen from Brazil
seen from Australia
seen from Italy
seen from Sweden
GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion...
GSK reorganization gains steam with Tesaro buyout, sale of Asia unit
GSK reorganization gains steam with Tesaro buyout, sale of Asia unit
The recent spate of cancer drugs securing FDA approval indicates that research and development in the area is progressing rapidly. So, it is natural that every pharmaceuticals company strives to get a share of that lucrative market. The decision by GlaxoSmithKline (GSK) this week to acquire an American cancer drug maker with a promising future is the right move by the British healthcare giant in…
View On WordPress
ROLAPITANT, ロラピタント;
ROLAPITANT HYDROCHLORIDE
Rolapitant HCl
Rolapitant hydrochloride
Sch 619734
SCH619734
UNII-57O5S1QSAQ
(5S ,8S)-8-[[(1R)-1-[3 ,5- Bis(trifluoromethyl)phenyl] ethoxy] methyl]-8-phenyl-1,7- diazaspiro[4.5]decan-2-one hydrochloride monohydrate.
CAS 914462-92-3
Empirical Formula: C25H26F6N2O2 · HCl · H2O, Molecular Weight: 555
USAN Name: Rolapitant hydrochloride, INN Name: rolapitantum or rolapitant
View On WordPress
Tesaro shares spike on buyout news, trading halted
Tesaro shares spike on buyout news, trading halted
Shares of Tesaro (TSRO), an oncology-focused biopharma company, skyrocketed after the news that it has been working with advisors for a possible sale. The stock, which opened at $26.46 today, reached a maximum of $38.35 and has jumped more than 30%. Because of the sudden spike, the trading of Tesaro shares was halted.
https://news.alphastreet.com/arena-pharmaceuticals-arna-stock-soars-on-agreem…
View On WordPress
TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities
FDA Approves Tesaro’s niraparib for ovarian cancer March 27, 2017
AstraZeneca Rivals Tesaro Using PARP Inhibitor with Strong Ovarian Cancer Study Results
AstraZeneca Rivals Tesaro Using PARP Inhibitor with Strong Ovarian Cancer Study Results
Mar 14, 2017
The PARP inhibitor of AstraZeneca, Lynparza, delay the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented recently. The strong benefits observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro. The new…
View On WordPress
Analyst Activity – Robert W. Baird Reiterates Outperform on Tesaro (NASDAQ:TSRO)
Analyst Activity – Robert W. Baird Reiterates Outperform on Tesaro (NASDAQ:TSRO)
Analyst Ratings For Tesaro (NASDAQ:TSRO) Today, Robert W. Baird reiterated its Outperform rating on Tesaro (NASDAQ:TSRO) with a price target of $127.00. There are 2 hold ratings, 13 buy ratings on the stock. The current consensus rating on Tesaro (NASDAQ:TSRO) is Buy (Score: 2.87) with a consensus target price of $119.66 per share, a potential 9.75% downside. Some recent analyst ratings include…
View On WordPress